World's Best Scientists 2026 revealed!

D-Index & Metrics

Economics and Finance

D-Index
41
Citations
6005
World Ranking
2208
National Ranking
263

Alan Haycox publication distribution in Economics and Finance in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Economics and Finance in 2026. The highlighted bar marks where Alan Haycox sits on this spectrum.

42–46 publications: 1 scientists 47–51 publications: 12 scientists 52–56 publications: 7 scientists 57–61 publications: 23 scientists 62–66 publications: 32 scientists 67–71 publications: 36 scientists 72–76 publications: 56 scientists 77–81 publications: 57 scientists 82–86 publications: 70 scientists 87–91 publications: 86 scientists 92–96 publications: 72 scientists 97–101 publications: 106 scientists 102–106 publications: 97 scientists 107–111 publications: 96 scientists 112–116 publications: 101 scientists 117–121 publications: 103 scientists 122–126 publications: 102 scientists 127–131 publications: 108 scientists 132–136 publications: 107 scientists 137–141 publications: 111 scientists 142–146 publications: 94 scientists 147–151 publications: 96 scientists 152–156 publications: 100 scientists 157–161 publications: 74 scientists 162–166 publications: 68 scientists 167–171 publications: 91 scientists 172–176 publications: 76 scientists 177–181 publications: 75 scientists 182–186 publications: 61 scientists 187–191 publications: 66 scientists 192–196 publications: 68 scientists 197–201 publications: 71 scientists 202–206 publications: 60 scientists 207–211 publications: 56 scientists 212–216 publications: 44 scientists 217–221 publications: 51 scientists 222–226 publications: 65 scientists 227–231 publications: 48 scientists 232–236 publications: 59 scientists 237–241 publications: 37 scientists 242–246 publications: 37 scientists 247–251 publications: 41 scientists 252–256 publications: 43 scientists 257–261 publications: 33 scientists 262–266 publications: 34 scientists 267–271 publications: 39 scientists 272–276 publications: 25 scientists 277–281 publications: 29 scientists 282–286 publications: 29 scientists 287–291 publications: 26 scientists 292–296 publications: 31 scientists 297–301 publications: 31 scientists 302–306 publications: 24 scientists 307–311 publications: 28 scientists 312–316 publications: 24 scientists 317–321 publications: 13 scientists 322–326 publications: 14 scientists 327–331 publications: 25 scientists 332–336 publications: 18 scientists 337–341 publications: 16 scientists 342–346 publications: 18 scientists 347–351 publications: 15 scientists 352–356 publications: 17 scientists 357–361 publications: 19 scientists 362–366 publications: 16 scientists 367–371 publications: 17 scientists 372–376 publications: 7 scientists 377–381 publications: 18 scientists 382–386 publications: 13 scientists 387–391 publications: 19 scientists 392–396 publications: 9 scientists 397–401 publications: 10 scientists 402–406 publications: 13 scientists 407–411 publications: 13 scientists 412–416 publications: 5 scientists 417–421 publications: 10 scientists 422–426 publications: 6 scientists 427–431 publications: 12 scientists 432–436 publications: 9 scientists 437–441 publications: 9 scientists 442–446 publications: 10 scientists 447–451 publications: 12 scientists 452–456 publications: 8 scientists 457–461 publications: 4 scientists 462–466 publications: 7 scientists 467–471 publications: 4 scientists 472–476 publications: 5 scientists 477–481 publications: 6 scientists 482–486 publications: 7 scientists 487–491 publications: 8 scientists 492–496 publications: 5 scientists 497–501 publications: 4 scientists 502–506 publications: 4 scientists 507–511 publications: 5 scientists 512–516 publications: 7 scientists 517–520 publications: 7 scientists 521+ publications: 99 scientists
42 publications 521+

This scientist: 127 publications — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 521 publications or more.

Alan Haycox D-index placement in Economics and Finance in 2026

The chart shows the D-index (discipline H-index) distribution of Economics and Finance scientists ranked by Research.com in 2026. The highlighted bar marks where Alan Haycox sits on this spectrum.

30 D-Index: 126 scientists 31 D-Index: 147 scientists 32 D-Index: 157 scientists 33 D-Index: 178 scientists 34 D-Index: 171 scientists 35 D-Index: 141 scientists 36 D-Index: 132 scientists 37 D-Index: 129 scientists 38 D-Index: 130 scientists 39 D-Index: 120 scientists 40 D-Index: 117 scientists 41 D-Index: 113 scientists 42 D-Index: 114 scientists 43 D-Index: 97 scientists 44 D-Index: 115 scientists 45 D-Index: 86 scientists 46 D-Index: 78 scientists 47 D-Index: 83 scientists 48 D-Index: 62 scientists 49 D-Index: 74 scientists 50 D-Index: 50 scientists 51 D-Index: 66 scientists 52 D-Index: 69 scientists 53 D-Index: 55 scientists 54 D-Index: 67 scientists 55 D-Index: 61 scientists 56 D-Index: 62 scientists 57 D-Index: 45 scientists 58 D-Index: 34 scientists 59 D-Index: 47 scientists 60 D-Index: 46 scientists 61 D-Index: 36 scientists 62 D-Index: 37 scientists 63 D-Index: 56 scientists 64 D-Index: 50 scientists 65 D-Index: 32 scientists 66 D-Index: 28 scientists 67 D-Index: 30 scientists 68 D-Index: 24 scientists 69 D-Index: 25 scientists 70 D-Index: 22 scientists 71 D-Index: 21 scientists 72 D-Index: 26 scientists 73 D-Index: 24 scientists 74 D-Index: 23 scientists 75 D-Index: 12 scientists 76 D-Index: 14 scientists 77 D-Index: 15 scientists 78 D-Index: 15 scientists 79 D-Index: 17 scientists 80 D-Index: 17 scientists 81 D-Index: 11 scientists 82 D-Index: 10 scientists 83 D-Index: 16 scientists 84 D-Index: 11 scientists 85 D-Index: 5 scientists 86 D-Index: 9 scientists 87 D-Index: 13 scientists 88 D-Index: 9 scientists 89 D-Index: 7 scientists 90 D-Index: 6 scientists 91 D-Index: 4 scientists 92 D-Index: 8 scientists 93 D-Index: 10 scientists 94 D-Index: 11 scientists 95 D-Index: 6 scientists 96 D-Index: 4 scientists 97 D-Index: 4 scientists 98 D-Index: 6 scientists 99 D-Index: 6 scientists 100 D-Index: 8 scientists 101+ D-Index: 100 scientists
30 D-Index 101+

This scientist: 41 D-Index — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 101 D-Index or more.

Overview

Alan Haycox is affiliated with the University of Liverpool in the United Kingdom. Their research spans a combination of medicine and economics, with significant contributions in subfields such as pediatrics, perinatology and child health, economics and econometrics, pathology and forensic medicine, public health, environmental and occupational health, and neurology.

Their work covers a diverse range of topics including multiple sclerosis research studies, acute lymphoblastic leukemia research, CNS lymphoma diagnosis and treatment, health systems with a focus on economic evaluations and quality of life, pharmaceutical economics and policy, pharmaceutical studies and practices, as well as maternal and perinatal health interventions.

Recent publications reflect this interdisciplinary approach. Notable papers include:

  • "Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies," 2021, published in Multiple Sclerosis and Related Disorders
  • "The Induction with Foley OR Misoprostol (INFORM) Study dataset. A dataset of 602 women with hypertensive disease in pregnancy, in India, randomised to either Foley catheter or oral misoprostol for induction of labour," 2021, published in BMC Research Notes

Haycox has collaborated frequently with several researchers in related fields, including Michael Levy, Ursula Becker, Cristina Costantino, Elisabetta Damonte, and Gaëlle Klingelschmitt. These collaborations align with the thematic concentration seen in Haycox's publications.

The scholar's works have appeared primarily in the following venues:

  • Multiple Sclerosis and Related Disorders
  • BMC Research Notes

Best Publications

  • Systematic review of cost effectiveness studies of telemedicine interventions.

    Pamela S Whitten;Frances S Mair;Alan Haycox;Carl R May

  • Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

    Jakub Adamski;Brian Godman;Brian Godman;Brian Godman;Gabriella Ofierska-Sujkowska;Bogusława Osińska

  • The impact of non‐compliance on the cost‐effectiveness of pharmaceuticals: a review of the literature

    Dyfrig A. Hughes;Adrian Bagust;Alan Haycox;Tom Walley

  • A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery

    Penny F Whiting;R Gupta;J Burch;R E Mujica Mota

  • Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.

    Brian Godman;Björn Wettermark;Mikael Hoffmann;Karolina Andersson

  • Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.

    Brian Barr Godman;Anna Bucsics;Patricia Vella Bonanno;Wija Oortwijn;Wija Oortwijn

  • Coronary artery stents: a rapid systematic review and economic evaluation

    R Hill;A Bagust;A Bakhai;R Dickson

  • Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation

    Y Dündar;A Boland;J Strobl;S Dodd

  • Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.

    Catherine Sermet;Veronique Andrieu;Brian Godman;Brian Godman;Brian Godman;Eric Van Ganse

  • The Iranian Health Insurance System; Past Experiences, Present Challenges And Future Strategies

    M Davari;A Haycox;T Walley

  • The implementation of managed entry agreements in Central and Eastern Europe : findings and implications

    Alessandra Ferrario;Diāna Arāja;Tomasz Bochenek;Tarik Čatić

  • Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

    Björn Wettermark;Björn Wettermark;Brian Godman;Karolina Andersson;Lars L. Gustafsson;Lars L. Gustafsson

  • Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

    Rickard E. Malmström;Brian B. Godman;Brian B. Godman;Brian B. Godman;Eduard Diogene;Christoph Baumgärtel

  • Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation

    A Boland;Y Dundar;A Bagust;A Haycox

  • A review of telemedicine cost-effectiveness studies:

    F S Mair;A Haycox;C May;T Williams

  • Clinical guidelines-the hidden costs.

    Alan Haycox;Adrian Bagust;Tom Walley

  • Accounting for Noncompliance in Pharmacoeconomic Evaluations

    Dyfrig A. Hughes;Adrian Bagust;Alan Haycox;Tom Walley

  • Enhancing the rational use of new medicines across European health care systems.

    Silvio Garattini;Vittorio Bertele;Brian Godman;Alan Haycox

  • Insight into recent reforms and initiatives in Austria: implications for key stakeholders

    Brian Godman;Anna Bucsics;Thomas Burkhardt;Alan Haycox

  • European countries with small populations can obtain low prices for drugs: Lithuania as a case history.

    Kristina Garuoliene;Brian Godman;Jolanta Gulbinovič;Björn Wettermark

  • The Health Economic Impact of Upper Gastrointestinal Symptoms in the General Population: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST)

    A Haycox;T Einarson;A Eggleston

Frequent Co-Authors

Brian Godman
Brian Godman University of Strathclyde
Zarko Alfirevic
Zarko Alfirevic University of Liverpool
Andrew Weeks
Andrew Weeks University of Liverpool
Chris Roberts
Chris Roberts University of Manchester
Tom Solomon
Tom Solomon University of Liverpool
Simon Capewell
Simon Capewell University of Liverpool
Stephen Campbell
Stephen Campbell University of Manchester
Carl May
Carl May London School of Hygiene & Tropical Medicine
Munir Pirmohamed
Munir Pirmohamed University of Liverpool

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Economics and Finance, exploring related online degrees can open new doors for career advancement. Specialized programs like online masters programs in project management provide essential skills in planning, leadership, and strategic thinking, all highly valued in today’s business landscape.

Fast-tracked education is also gaining popularity. One-year MBA programs allow professionals to rapidly gain management expertise without a multi-year commitment. For those with an entrepreneurial mindset, choosing the cheapest MBA entrepreneurship online program can help develop business ideas while managing costs effectively.

Even at the undergraduate level, degrees like a Bachelor in Project Management are increasingly relevant. But students often wonder, is a bachelor degree in project management worth it? The answer depends on your career goals and the demand for strategic project leaders, which continues to grow across industries.

By choosing the right online pathway, you can tailor your studies to rapidly changing market needs and broaden your professional opportunities in finance, management, and entrepreneurship.

Best Scientists Citing Alan Haycox

Trending Scientists